latest news releases from the newsroom
PharmChem Reports First Quarter 2003 Results
HALTOM CITY, Texas, May 15, 2003 (PRIMEZONE) -- PharmChem, Inc. (Nasdaq:PCHM) announced that its net sales for the first quarter
ended March 31, 2003 were $6,335,000, a decrease of 15.3% from first quarter 2002's net sales from continuing operations of $7,476,000. The Company reported a loss from continuing operations for the current quarter of $733,000, or $0.13 per share, versus a loss from continuing operations of $310,000, or $0.05 per share, a year ago.
Tele2: Annual General Meeting of Shareholders
STOCKHOLM, Sweden, May 15, 2003 (PRIMEZONE) -- Tele2 AB, ("Tele2"), (Nasdaq:TLTOA) (Nasdaq:TLTOB) (Stockholm:TEL2A) (Stockholm:TEL2B), the leading alternative pan-European telecommunications company, today announced that the company's Annual General Meeting (AGM) of shareholders held today in Stockholm re-elected Marc Beuls, Vigo Carlund, Bruce Grant, Sven Hagstromer and Hakan Ledin as Board members. John Shakeshaft and Cristina Stenbeck were elected as new members of the Board of Directors. Mikael Winkvist was elected as deputy auditor.
Actelion Invitation to Investor Conference Call / Webcast
ALLSCHWIL, Switzerland, May 15, 2003 (PRIMEZONE) -- Actelion to host Conference Call/Webcast following ATS presentation by opinion leader Dr Vallerie McLaughlin on 19 May 2003 (Seattle)At the upcoming American Thoracic Society (ATS) Scientific Sessions to be held in Seattle (Washington/USA) on 19 May 2003, Dr. Vallerie McLaughlin, MD, Rush Presbyterian Medical Center, Chicago, will present an analysis of long-term follow-up data, which showed a positive long-term survival benefit involving 169 primary pulmonary hypertension patients, who were treated with Tracleer(R) as first line treatment and were enrolled in the Tracleer(R) pivotal registration studies.